Skip to main content
OpenTrials
Completed

NCT Number: NCT05532475

Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion

To assess the levels of TNF- α in vitreous samples of patients with retinal vein occlusion prior to administration of intravitreal anti-VEGF and compare them to levels in vitreous samples of normal subjects so as to investigate the association of vitreous tumor necrosis factor with the pathogenesis of retinal vein occlusion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Retinal Vein Occlusion Cardiovascular Diseases Embolism and Thrombosis Eye Diseases Retinal Diseases Thrombosis Vascular Diseases Venous Thrombosis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Kasr ALainy University hospital

Cairo, 12916, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Any patient with retinal vein occlusion not older than 6 months with no history of Anti-VEGF injection

Exclusion criteria

  • Diabetic patients.
  • Other causes of retinal vascular diseases.
  • Patients with history of treatment of retinal vein occlusion.
  • Previous intraocular surgery except cataract surgery performed 6 months before the study.
  • Subjects with severe systemic inflammatory diseases
  • Retinal vein occlusion secondary to retinal vasculitis.
  • All retinal pathologies.
  • Patients receiving Systemic steroids or Immunosuppressive therapy.

Treatment and study plan

measurement of vitreous level of tumor necrosis factor alpha

Diagnostic Test

measurement of vitreous level of tumor necrosis factor alpha using ELISA technique

Primary outcomes

  1. to assess vitreous level of tumor necrosis factor alpha in retinal vein occlusion and compare it to patient undergoing cataract surgery

    Time frame: Day 1

Sponsors and collaborators

Lead sponsor

Kasr El Aini Hospital

Other

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
Sep 8, 2022
Registry last updated
Nov 27, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.